Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of solifenacin + mirabegron versus monotherapy in overactive bladder
2012-005736-29Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder (OAB) comparing Solifenacin + mirabegron combination, Solifenacin monotherapy and Mirabegron monotherapy (3 arms). Primary endpoint: Treatment-emergent adverse events. Started Nov 2013; status: completed.
02
Drugs
solifenacinmirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2012-005736-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005736-29.